



GlobalData»
PharmaPoint

**HER2-POSITIVE BREAST CANCER –
GLOBAL DRUG FORECAST AND MARKET ANALYSIS
TO 2023**

Executive Summary

HER2-Positive Breast Cancer: Key Metrics in the Eight Major Pharmaceutical Markets, 2013–2023	
2013 Epidemiology	
Breast cancer incident cases	853,902
HER2-positive breast cancer incident cases	182,487
2013 Market Sales	
US	\$2.41bn
5EU	\$1.99bn
Japan	\$126m
China	\$425m
Total	\$4.95bn
Late-Stage Pipeline Assessment	
Number of drugs in Phase III profiled	2
Most Promising Late-Stage Pipeline Drugs	Peak-Year Sales
Neratinib (Puma Biotechnology)	\$90m
Key Events (2013–2023)	Level of Impact
Herceptin (trastuzumab) patent expiry in the 5EU in 2014	↓↓↓
Launch of biosimilar trastuzumab in the 5EU in 2015	↓↓↓
Approval of Perjeta (pertuzumab) in the adjuvant setting in 2017	↑↑
Launch of neratinib in the metastatic setting in 2018	↑↑
Launch of Kadcyra (ado-trastuzumab emtansine, T-DM1) in the adjuvant setting in 2019	↑↑
2023 Market Sales	
US	\$7.95bn
5EU	\$3.90bn
Japan	\$239m
China	\$613m
Total	\$12.70bn
Source: GlobalData	
5EU = France, Germany, Italy, Spain, and UK	

The table above presents the key metrics for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer in the eight major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, and China) during the forecast period from 2013–2023.

HER2-Positive Breast Cancer Market to Increase by 2.5-Fold by 2023

In the 8MM in this report, GlobalData valued the HER2-positive breast cancer market at \$4.95 billion in 2013, and expects the market to increase to \$12.70 billion in 2023, at a Compound Annual Growth Rate (CAGR) of 9.88%. The US contributes almost half of the total market sales in both 2013 and 2023.

The top drivers of growth in the HER2-positive breast cancer market during the forecast period include:

- The rapid uptake of the premium-priced biologics, Perjeta and Kadcyra, in all settings of the disease, where their sales will increase at a CAGR of 30.2% and 35.1%, respectively, during the forecast period. By 2023, together, they will capture 75% of the total HER2-positive breast cancer market.
- The launch of Perjeta and Kadcyra in early disease in the neoadjuvant and adjuvant settings will have the greatest impact on the HER2-positive breast cancer therapeutics market, with both agents capturing 77% of the non-metastatic market by 2023.

Executive Summary


- Combinations of branded therapies in both the early-stage and metastatic settings will inflate the annual cost of therapy (ACOT). For instance, the ACOT for the combination of Perjeta with Herceptin is three times that for Herceptin alone in both adjuvant and metastatic settings in the US.
- A growing aging population and an increasing incidence of HER2-positive breast cancer cases across the 8MM. This is especially the case in urban China, where over the forecast period, the female population will increase faster than in any other market covered in this report, at a CAGR of 2.9%.

Major barriers to growth in the HER2-positive breast cancer market include:

- The patent expiry of Herceptin in the 5EU in 2014, and in the US in 2019, will negatively impact the market, as Herceptin sales will decrease at a CAGR of 4.7% by 2023.
- Tighter control of healthcare total expenditures in the 5EU will be a significant hurdle for the uptake of new premium-priced drugs, especially when they are used in combination. In the US, the Affordable Care Act (ACA) is creating a new cost-conscious environment that could impact the free-pricing system.
- Inconsistent healthcare coverage across China continues to be a barrier to growth in the HER2-positive breast cancer market. In addition, there is low participation in breast

screening programs in China, and there are drug reimbursement issues as well.

The figure shown below provides the global sales for HER2-positive breast cancer during the forecast period.



Executive Summary


Roche Retains Its Monopoly in the HER2-Positive Breast Cancer Market

In 2013, Roche was the undeniable global leader in the HER2-positive breast cancer market, capturing 95% of the total HER2-targeted drug sales. This leadership was built on the success of Herceptin, which has been the standard of care in all settings of HER2-positive breast cancer since its launch in 1998. Herceptin alone accounted for 84% of the HER2-positive market in 2013. With a looming patent expiry for Herceptin, Roche recently launched two new anti-HER2 monoclonal antibodies (mAbs): Perjeta in 2012, and Kadcyla in 2013. Roche's mAbs have no real competition in the market, and as such, these new agents are forecast to see rapid uptake, thereby maintaining Roche's dominance of the market. By 2023, GlobalData expects that Roche's share of the HER2-positive breast cancer market will exceed \$12 billion.

To enter this challenging market, competitors have been focusing on the development of tyrosine kinase inhibitors (TKIs). In 2007, GlaxoSmithKline (GSK) launched Tykerb (lapatinib), the first HER2-targeted TKI. Puma and Boehringer Ingelheim are currently investigating TKIs for breast cancer; however, the role for TKIs remains small, as Tykerb accounted for less than 5% of the HER2-positive market in 2013. Indeed, the role of TKIs in early disease appears very uncertain. GlobalData foresees that TKIs will only be used in later lines of therapy, after the use of Roche's mAbs. By the end

of the forecast period in 2023, GlobalData anticipates that the HER2-positive TKI market will have decreased to \$198m, from \$212m in 2013. Ultimately, GlobalData believes that Roche's monopoly of this market will only be challenged by companies with innovative product portfolios, such as Novartis, and Pfizer.

The figure shown below provides an analysis of the company portfolio gap in HER2-positive breast cancer during the forecast period.



Executive Summary

Kadcyla Will Experience Strong Uptake Across the 8MM

Since launching for use in the second-line metastatic breast cancer setting in February 2013, Roche's Kadcyla has been rapidly adopted in the US. In 2013, Kadcyla captured 10% of the US market and 5% of the US, 5EU, and Japan. In comparison, only 7% of patients in these markets in which Perjeta was launched received Perjeta in combination with Herceptin in the first-line setting, despite Perjeta having been launched six months before Kadcyla. In fact, key opinion leaders (KOLs) and global prescribers interviewed by GlobalData praised the high efficacy and low side effect profile of Kadcyla, which is expected to result in its continued strong uptake across the 8MM. With expected approval in the first-line setting in 2017, and as an adjuvant therapy in 2019, GlobalData forecasts Kadcyla to become the leader in the HER2-positive market, capturing 38% of the total market by 2023.

Non-Metastatic Breast Cancer Represents the Largest Market for HER2-Targeting Agents

In 2013, the combined sales of anti-HER2 agents used in the neoadjuvant and adjuvant treatment of early-stage (non-metastatic) breast cancer represented 55% of the total market. The use of Herceptin is particularly strong in the adjuvant setting, where its sales contributed to 99% of the total adjuvant market, and 49% of total Herceptin sales, in 2013. During the forecast period, GlobalData expects the adjuvant and neoadjuvant

settings to remain the largest markets, and forecasts their sales to reach \$8.60 billion in 2023, representing 67% of the total HER2-positive market. This increase in market size will be driven primarily by the uptake of premium-priced therapies, such as Perjeta, which was the first drug to receive approval in the neoadjuvant setting in the US in 2013.

The dynamism of the adjuvant and neoadjuvant markets has prompted many companies to try to position their products in these settings, especially since the early lines of therapy for metastatic disease are considered to be inaccessible due to Roche's monopoly in this area. TKIs were of particular interest, since they offer greater convenience than mAbs, but the negative results for Tykerb in the adjuvant setting, which were released in early 2014, showed that TKIs may not be a good fit for this setting. Generally, TKIs have more side effects, with little efficacy benefit, compared with antibodies. Therefore, GlobalData believes that the adjuvant and neoadjuvant settings will remain an exclusive market for anti-HER2 mAbs, hence constituting the most lucrative opportunity for biosimilar developments. In 2023, GlobalData expects the biosimilar market for trastuzumab to be worth \$962m in 8MM, with 65% of sales being in the neoadjuvant and adjuvant settings.

Executive Summary

Better Treatment for Brain Metastases Remains the Most Pressing Unmet Need

Although the efficacy of HER2-targeted therapies substantially improves the life expectancy of patients with HER2-positive disease, by nature, HER2-positive breast cancer is still a more aggressive form of the disease, with a poorer prognosis and worse outcomes than for patients with HER2-negative (and hormone receptor [HR]-positive) disease. Two unmet needs are of high importance to increase survival in HER2-positive disease:

- The effective treatment of central nervous system (CNS) metastases
- The treatment of disease that has become resistant to HER2-targeting therapies

HER2-targeting mAbs have failed to deliver benefits to patients with brain metastases, because they cannot pass the blood-brain barrier. TKIs, such as Tykerb or neratinib, may be effective here; however, resistance to kinase inhibitors is common, so innovative therapies to treat TKI-resistant HER2-positive disease will also be required. The agents in early-stage development that target phosphoinositide 3-kinase (PI3K), such as NVP-BYL719 and the cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, palbociclib, have both been suggested for use in the treatment of anti-HER2-resistant breast cancer. With impressive results in the HER2-negative setting, as well as some evidence of blood-brain barrier penetration, these

agents also have the possibility of addressing the unmet needs that plague the HER2-positive market.

Future Breast Cancer Therapies Will Unite the HER2-Positive and HER2- Negative Markets

The agents in the most advanced stages of development for HER2-positive breast cancer are the TKIs — namely, Boehringer Ingelheim's (BIs) Gilotrif (afatinib) and Puma's neratinib. However, recent study results show that TKIs may not demonstrate a great benefit over the existing therapies. GlobalData foresees that TKIs will be used in these scenarios: almost exclusively in later lines of therapy; after the failure of anti-HER2 therapies in the earlier stages of metastatic disease; or for patients with known brain metastases. Puma is positioning neratinib for use as a later line of therapy, and in this setting (second-line metastatic and beyond), GlobalData forecasts neratinib to generate \$128m in sales by 2023.

A very limited number of agents are being developed specifically for HER2-positive breast cancer. For example, Array's ARRY-380 (ONT-380) is another TKI that is currently in Phase I/II for HER2-positive disease, while Galena is developing NeuVax (nelipepimut-S), a vaccine that is also being investigated in HER2-negative disease. In fact, GlobalData believes that the most promising agents for HER2-positive disease are being developed primarily for HER2-negative disease. In particular, KOLs have expressed interest in PI3K

Executive Summary

inhibitors, such as Novartis's BYL-719, as well as in CDK 4/6 inhibitors, such as Pfizer's palbociclib and Novartis's LEE011, in the treatment of HER2-positive disease. Other drugs in the early phases of development include Daiichi Sankyo's patritumab (U3-1287), which is an anti-HER3 mAb, and Syntha's ganetespib (STA-9090), which is a heat shock protein 90 (HSP90) inhibitor. However, the clinical relevance of these agents still remains to be established.

The HER2-positive market has become very mature since the launch of anti-HER2 antibodies. For agents to be successful, the strategy may not be to target HER2 specifically, but rather, to target a separate pathway that is applicable to both HER2-positive and -negative disease, thus unifying the breast cancer market.


"For HER2-negative disease, [there] is much easier uptake [of drugs], so that is why they went there [first]. But obviously, those kinds of drugs could be of high interest in HER2-positive disease, too."

OUS Key Opinion Leader, April 2014

"...drugs like palbociclib will be very interesting in HER2-positive disease, and some of them do cross the blood-brain barrier, so...those might be interesting approaches."

US Key Opinion Leader, January 2014

The figure shown below provides a competitive assessment of the most promising agents for HER2-positive breast cancer during the forecast period.



Executive Summary

What Do Physicians Think?

KOLs praised the efficacy of Kadcyla for metastatic disease, and are already anticipating its use in earlier settings.

“The effectiveness with the lack of toxicity is one of the big attractions of T-DM1 [Kadcyla].”

OUS Key Opinion Leader, April 2014

“I am a big believer in TDM-1. I did lots of those first trials with TDM-1, and I think it’s a great drug. And so, we are very hopeful that it’s going to have positive results in the different adjuvant trials that are underway.”

US Key Opinion Leader, January 2014

“We are hopeful that HER2-positive disease will be essentially cured in the next decade, or shorter, by the new agents that we have, that all clearly showed a dramatic benefit in patients who had received prior trastuzumab in the case of Kadcyla, and in those who hadn’t [been treated with prior trastuzumab] in the case of Perjeta. I mean, there was clearly an improved survival. So, that suggests that by adding those agents in some form in the early-stage setting, that we will cure more patients with HER2-positive disease.”

US Key Opinion Leader, January 2014

“If [Kadcyla] turned out to be an active agent in the early-stage setting, that’s where it will get used. I mean, ultimately, there is not going to be a desire to hold back on drugs — [that is,] to use better drugs later. We are going to want to use our best drugs up front. If T-DM1 is better, and we can use T-DM1 up front and have a better result in terms of efficacy, and have a lower toxicity, then that’s what will be used.”

US Key Opinion Leader, December 2013

KOLs still believe there is room for TKIs, especially after disease progression following the use of anti-HER2 mAbs. Neratinib, in particular, is a TKI under development that they are looking forward to using in the metastatic setting.

“What I tell people is, at some point, you should be using a lapatinib combination, either with Herceptin or with Xeloda [(capecitabine)], and then you should be using whatever other chemotherapies with Herceptin that you have still left — eribulin, navelbine, gemcitabine — and I don’t think the order matters.”

US Key Opinion Leader, January 2014

Executive Summary

"In my opinion, it [Tykerb] has always been a very promising drug, but the promise...has never been held in the clinic, probably because of scheduling, which doesn't allow the full potential of anti-tumor activity because you have to stop at a certain point because of unacceptable toxicity. The same is for neratinib or afatinib; probably playing with the schedule and ensuring optimal exposure of the tumor to optimal saturation of receptors may really reveal additional properties of these drugs in the treatment of trastuzumab-, or antibody-, in general, refractory HER2-positive tumors."

OUS Key Opinion Leader, April 2014

"[Neratinib is] such a potent oral tyrosine kinase inhibitor [that], maybe instead of pitching themselves against Herceptin, they could look at how they are going to work in patients who don't respond, or who have higher-risk disease, or afterwards, etcetera."

US Key Opinion Leader, January 2014

"[Neratinib is a] drug that has a very impressive anti-tumor activity, very impressive. I remember the Phase II study in patients [who were] never treated before with anti-tumor agents, that, as a single agent it, gave a 50% response rate, which is quite remarkable."

OUS Key Opinion Leader, April 2014

"The real difficulty is that the market has moved on so much from when the trials [for neratinib and Gilotrif] have been done, and one assumes these drugs are going to be expensive, with a lot of toxicity, and without a clear data set to support them, because everyone has moved on to giving totally different treatment. I think it's going to be much harder to get those in."

OUS Key Opinion Leader, April 2014

Effective therapies for the treatment of brain metastases remain the biggest unmet need, and KOLs are interested to see how cyclin-dependant kinase inhibitors, which are currently in development for HER2-negative disease, can deliver in this setting.

"...HER2-positive patients very frequently get brain metastases....Radiation is a good treatment, but it doesn't last forever, so progression in the brain after radiation is a real problem. We do not have any good treatments for that; that's an unmet medical need."

US Key Opinion Leader, January 2014

Executive Summary

“Another class of drugs which has activity in HER2-positive disease, but is being pursued in ER [estrogen-receptor]-positive disease, of course, are CDK 4/6 inhibitors, and those are quite interesting....They have the potential of crossing the blood-brain barrier, and are highly effective in ER-positive disease, and I’m hopeful [that we] are going to really change the course of patients who have ER-positive breast cancer.”

US Key Opinion Leader, January 2014

Table of Contents

1 Table of Contents

1	Table of Contents	11
1.1	List of Tables	18
1.2	List of Figures	23
2	Introduction	26
2.1	Catalyst.....	26
2.2	Related Reports	26
2.3	Upcoming Related Reports	27
3	Disease Overview.....	28
3.1	Etiology and Pathophysiology	28
3.1.1	Etiology	28
3.1.2	Pathophysiology	28
3.2	Basic Breast Anatomy	30
3.3	Breast Cancer Staging	31
3.4	Prognosis	32
3.5	Quality of Life	33
3.6	Symptoms	35
4	Epidemiology	36
4.1	Disease Background	36
4.2	Risk Factors and Comorbidities	37
4.2.1	A family history of breast cancer and BRCA1/2 gene mutations significantly increase the breast cancer risk	38
4.2.2	Reproductive hormonal factors influence the risk of breast cancer	39
4.2.3	Modifiable lifestyle-related factors increase the risk of mortality in breast cancer patients	41
4.2.4	Screening programs have been shown to reduce breast cancer mortality, although the benefits need to be carefully weighed against the risks	43
4.3	Global Trends	45

Table of Contents

4.3.1	Incidence.....	45
4.3.2	Prevalence and Survival.....	51
4.4	Forecast Methodology.....	55
4.4.1	Sources Used.....	56
4.4.2	Sources Not Used	61
4.4.3	Forecast Assumptions and Methods	61
4.5	Epidemiological Forecast for Breast Cancer (2013–2023) – Diagnosed Incident Cases ...	65
4.5.1	Diagnosed Incident Cases of Breast Cancer.....	65
4.5.2	Diagnosed Incident Cases of Breast Cancer by Age	67
4.5.3	Diagnosed Incident Cases of Breast Cancer by Menopausal Status	69
4.5.4	Diagnosed Incident Cases of Breast Cancer Segmented by Stage at Diagnosis.....	71
4.5.5	Age-Standardized Diagnosed Incidence Rate of Breast Cancer.....	72
4.6	Epidemiological Forecast for Breast Cancer (2013–2023) — Diagnosed Prevalent Cases	73
4.6.1	Five-Year Diagnosed Prevalent Cases of Breast Cancer	73
4.6.2	Five-Year Diagnosed Prevalent Cases by Menopausal Status.....	75
4.6.3	Five-Year Diagnosed Prevalent Cases by Hormone Receptor Subtypes.....	76
4.7	Discussion	78
4.7.1	Epidemiological Forecast Insight.....	78
4.7.2	Limitations of the Analysis.....	80
4.7.3	Strengths of the Analysis.....	81
5	Disease Management.....	83
5.1	Treatment Overview.....	83
5.1.1	Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB).....	83
5.1.2	Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA).....	84
5.1.3	Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)	87
5.2	US.....	90
5.2.1	Diagnosis	90

Table of Contents

5.2.2	Clinical Practice.....	90
5.3	France	93
5.3.1	Diagnosis	93
5.3.2	Clinical Practice.....	94
5.4	Germany.....	96
5.4.1	Diagnosis	96
5.4.2	Clinical Practice.....	97
5.5	Italy	99
5.5.1	Diagnosis	99
5.5.2	Clinical Practice.....	99
5.6	Spain	102
5.6.1	Diagnosis	102
5.6.2	Clinical Practice.....	103
5.7	UK.....	104
5.7.1	Diagnosis	104
5.7.2	Clinical Practice.....	105
5.8	Japan.....	108
5.8.1	Diagnosis	108
5.8.2	Clinical Practice.....	108
5.9	China	109
5.9.1	Diagnosis	109
5.9.2	Clinical Practice.....	110
6	Competitive Assessment	112
6.1	Overview.....	112
6.2	Product Profiles – HER2-Targeted Therapies	113
6.2.1	Herceptin (trastuzumab).....	113
6.2.2	Tykerb (lapatinib)	120

Table of Contents

6.2.3	Perjeta (pertuzumab).....	125
6.2.4	Kadcyla (ado-trastuzumab emtansine, T-DM1)	130
6.3	Product Profiles – General Targeted Therapies	134
6.3.1	Afinitor (everolimus)	134
6.3.2	Xeloda (capecitabine).....	138
6.3.3	Avastin (bevacizumab).....	141
6.3.4	Halaven (eribulin mesylate).....	144
6.3.5	Abraxane (nab-paclitaxel).....	148
6.3.6	Ixempra (ixabepilone).....	151
6.4	Hormonal Agents	155
6.4.1	Tamoxifen	155
6.4.2	Faslodex (fulvestrant).....	155
6.4.3	Aromatase Inhibitors	156
7	Unmet Need and Opportunity	158
7.1	Overview.....	158
7.2	Brain Metastases	159
7.2.1	Unmet Need	159
7.2.2	Gap Analysis.....	159
7.2.3	Opportunity	161
7.3	Resistance to HER2-Targeting Therapies	161
7.3.1	Unmet Need	161
7.3.2	Gap Analysis.....	162
7.3.3	Opportunity	163
8	Pipeline Assessment.....	165
8.1	Overview.....	165
8.2	Promising Drugs in Clinical Development.....	166
8.2.1	Gilotrif (afatinib).....	166

Table of Contents

8.2.2	Neratinib.....	171
8.3	Promising Drugs in Early-Stage Development.....	175
8.3.1	Palbociclib.....	177
8.3.2	NeuVax (nelipepimut-S)	181
8.3.3	Patritumab.....	185
8.3.4	Ganetespib.....	188
8.3.5	ARRY-380 (ONT-380).....	191
8.3.6	NVP-BYL719.....	194
8.4	Biosimilars	196
9	Current and Future Players.....	198
9.1	Overview.....	198
9.2	Trends in Corporate Strategy.....	201
9.3	Company Profiles.....	203
9.3.1	Roche/Genentech	203
9.3.2	GlaxoSmithKline.....	205
9.3.3	Boehringer Ingelheim	207
9.3.4	Novartis.....	208
9.3.5	Pfizer.....	211
10	Market Outlook	214
10.1	Global Markets.....	214
10.1.1	Forecast.....	214
10.1.2	Drivers and Barriers – Global Issues	219
10.2	United States	222
10.2.1	Forecast.....	222
10.2.2	Key Events.....	225
10.2.3	Drivers and Barriers	225
10.3	France	228

Table of Contents

10.3.1	Forecast	228
10.3.2	Key Events	231
10.3.3	Drivers and Barriers	231
10.4	Germany	233
10.4.1	Forecast	233
10.4.2	Key Events	236
10.4.3	Drivers and Barriers	236
10.5	Italy	238
10.5.1	Forecast	238
10.5.2	Key Events	241
10.5.3	Drivers and Barriers	241
10.6	Spain	243
10.6.1	Forecast	243
10.6.2	Key Events	246
10.6.3	Drivers and Barriers	246
10.7	United Kingdom	248
10.7.1	Forecast	248
10.7.2	Key Events	251
10.7.3	Drivers and Barriers	251
10.8	Japan	254
10.8.1	Forecast	254
10.8.2	Key Events	257
10.8.3	Drivers and Barriers	257
10.9	China	259
10.9.1	Forecast	259
10.9.2	Key Events	262
10.9.3	Drivers and Barriers	262

Table of Contents

11	Appendix.....	265
11.1	Bibliography	265
11.2	Abbreviations	295
11.3	Methodology	303
11.4	Forecasting Methodology.....	303
11.4.1	Diagnosed HER2-Positive Breast Cancer Patients.....	303
11.4.2	Percent Drug-Treated Patients.....	304
11.4.3	Drugs Included in Each Therapeutic Class.....	304
11.4.4	Launch and Patent Expiry Dates	305
11.4.5	General Pricing Assumptions	306
11.4.6	Individual Drug Assumptions.....	307
11.4.7	Generic Erosion	316
11.4.8	Pricing of Pipeline Agents.....	316
11.5	Primary Research – KOLs Interviewed for this Report	318
11.6	Primary Research – Prescriber Survey	320
11.7	About the Authors	321
11.7.1	Analyst.....	321
11.7.2	Therapy Area Director.....	321
11.7.3	Epidemiologist.....	322
11.7.4	Acting Director of Epidemiology.....	322
11.7.5	Global Head of Healthcare	323
11.8	About GlobalData.....	324
11.9	Disclaimer	324

Table of Contents

1.1 List of Tables

Table 1:	AJCC Stage Definitions for Breast Cancer	32
Table 2:	Prognosis for Breast Cancer in the US	33
Table 3:	Selected Major Risk Factors and Comorbidities for Breast Cancer	38
Table 4:	Breast Cancer Mortality Attributable to Lifestyle-Related Risk Factors.....	42
Table 5:	8MM, Current Status and Plans of Large-Scale Breast Cancer Screening Programs.....	44
Table 6:	8MM, Relative Survival Rate for Breast Cancer, All Ages*, Women, %, 1991–2004**	51
Table 7:	Conversion of Common Staging Systems for Breast Cancer Used in the Forecast.....	55
Table 8:	8MM, Sources of the Breast Cancer Diagnosed Incidence Data Used in the Epidemiological Forecast.....	56
Table 9:	8MM, Diagnosed Incident Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013–2023	66
Table 10:	8MM, Diagnosed Incident Cases of Breast Cancer by Age, Women, N (Row %), 2013	68
Table 11:	8MM, Diagnosed Incident Cases of Breast Cancer by Menopausal Status, Ages ≥20 Years, Women, N (Row %), 2013	70
Table 12:	8MM, Diagnosed Incident Cases of Breast Cancer by Stage at Diagnosis, Ages ≥20 Years, Women, N, 2013	71
Table 13:	8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013–2023	74
Table 14:	8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Hormone Receptor Subtypes, Ages ≥20 Years, Women, N, 2013.....	77
Table 15:	Treatment Guidelines for HER2-Positive Breast Cancer	89
Table 16:	Product Profile – Herceptin.....	115
Table 17:	Clinical Studies for Herceptin in the Adjuvant Setting	117
Table 18:	Herceptin SWOT Analysis, 2013.....	119
Table 19:	Global Sales Forecast (\$m) for Herceptin, 2013–2023	120
Table 20:	Product Profile – Tykerb	122

Table of Contents

Table 21: Tykerb SWOT Analysis, 2013.....	124
Table 22: Global Sales Forecast (\$m) for Tykerb, 2013–2023	125
Table 23: Product Profile – Perjeta.....	127
Table 24: Perjeta SWOT Analysis, 2013	129
Table 25: Global Sales Forecast (\$m) for Perjeta, 2013–2023.....	129
Table 26: Product Profile – Kadcyla	131
Table 27: Kadcyla SWOT Analysis, 2013.....	133
Table 28: Global Sales Forecast (\$m) for Kadcyla, 2013–2023	134
Table 29: Product Profile – Afinitor.....	136
Table 30: Afinitor SWOT Analysis, 2013.....	137
Table 31: Product Profile – Xeloda.....	139
Table 32: Xeloda SWOT Analysis, 2013.....	141
Table 33: Product Profile – Avastin	142
Table 34: Summary of Avastin Phase III Clinical Trials in Metastatic Breast Cancer	143
Table 35: Avastin SWOT Analysis, 2013.....	144
Table 36: Product Profile – Halaven.....	145
Table 37: Halaven SWOT Analysis, 2013.....	147
Table 38: Global Sales Forecast (\$m) for Halaven, 2013–2023	148
Table 39: Product Profile – Abraxane.....	149
Table 40: Abraxane SWOT Analysis, 2013.....	150
Table 41: Global Sales Forecast (\$m) for Abraxane, 2013–2023.....	151
Table 42: Product Profile – Ixempra	152
Table 43: Ixempra SWOT Analysis, 2013.....	154
Table 44: Global Sales Forecast (\$m) for Ixempra, 2013–2023	154

Table of Contents

Table 45: Summary of Minor Therapeutic Classes Used to Treat HER-2 positive breast cancer, 2013.....	157
Table 46: Unmet Need and Opportunity in HER2-Positive Breast Cancer.....	158
Table 47: Product Profile – Gilotrif.....	168
Table 48: Gilotrif SWOT Analysis, 2014	170
Table 49: Product Profile – Neratinib.....	172
Table 50: Neratinib SWOT Analysis, 2013	175
Table 51: Global Sales Forecast (\$m) for Neratinib, 2013–2023.....	175
Table 52: Comparison of Therapeutic Classes in Development for HER2-Positive/HER2-Negative Breast Cancer, 2014	176
Table 53: HER2-Positive Breast Cancer – Early-Phase Pipeline, 2014.....	177
Table 54: Product Profile – Palbociclib.....	179
Table 55: Palbociclib SWOT Analysis, 2014.....	181
Table 56: Product Profile – NeuVax	183
Table 57: NeuVax SWOT Analysis, 2014.....	185
Table 58: Product Profile – Patritumab.....	186
Table 59: Patritumab SWOT Analysis, 2014.....	188
Table 60: Product Profile – Ganetespib.....	189
Table 61: Ganetespib SWOT Analysis, 2014.....	191
Table 62: Product Profile – ARRY-380	192
Table 63: ARRY-380 SWOT Analysis, 2014.....	193
Table 64: Product Profile – NVP-BYL719.....	194
Table 65: NVP-BYL719 SWOT Analysis, 2014.....	195
Table 66: Trastuzumab Biosimilars, 2014.....	197
Table 67: Key Companies in the HER2-Positive Breast Cancer Market in the 8MM, 2013–2023.....	199
Table 68: Roche’s HER2-Positive Breast Cancer Portfolio Assessment, 2014.....	204

Table of Contents

Table 69: Roche SWOT Analysis, 2014	205
Table 70: GSK's HER2-Positive Breast Cancer Portfolio Assessment, 2014.....	206
Table 71: GSK SWOT Analysis, 2014	207
Table 72: BI's HER2-Positive Breast Cancer Portfolio Assessment, 2014.....	208
Table 73: BI SWOT Analysis, 2014	208
Table 74: Novartis' HER2-Positive Breast Cancer Portfolio Assessment, 2014.....	210
Table 75: Novartis SWOT Analysis, 2014.....	210
Table 76: Pfizer's HER2-Positive Breast Cancer Portfolio Assessment, 2014.....	212
Table 77: Pfizer SWOT Analysis, 2014	213
Table 78: Global Sales Forecast (\$m) for HER2-Positive Breast Cancer, 2013–2023	216
Table 79: Global HER2-Positive Breast Cancer Market – Drivers and Barriers, 2013–2023	219
Table 80: Sales Forecast (\$m) for HER2-Positive Breast Cancer in the US, 2013–2023	223
Table 81: Key Events Impacting Sales for HER2-Positive Breast Cancer in the US, 2013–2023	225
Table 82: US HER2-Positive Breast Cancer Market – Drivers and Barriers, 2013–2023	225
Table 83: Sales Forecast (\$m) for HER2-Positive Breast Cancer in France, 2013–2023.....	229
Table 84: Key Events Impacting Sales for HER2-Positive Breast Cancer in France, 2013–2023.....	231
Table 85: French HER2-Positive Breast Cancer Market – Drivers and Barriers, 2013–2023	231
Table 86: Sales Forecast (\$m) for HER2-Positive Breast Cancer in Germany, 2013–2023	234
Table 87: Key Events Impacting Sales for HER2-Positive Breast Cancer in Germany, 2013–2023	236
Table 88: German HER2-Positive Breast Cancer Market – Drivers and Barriers, 2013–2023	236
Table 89: Sales Forecast (\$m) for HER2-Positive Breast Cancer in Italy, 2013–2023	239
Table 90: Key Events Impacting Sales for HER2-Positive Breast Cancer in Italy, 2013–2023	241
Table 91: Italian HER2-Positive Breast Cancer Market – Drivers and Barriers, 2013–2023.....	241
Table 92: Sales Forecast (\$m) for HER2-Positive Breast Cancer in Spain, 2013–2023.....	244

Table of Contents

Table 93: Key Events Impacting Sales for HER2-Positive Breast Cancer in Spain, 2013–2023.....	246
Table 94: Spanish HER2-Positive Breast Cancer Market – Drivers and Barriers, 2013–2023	246
Table 95: Sales Forecast (\$m) for HER2-Positive Breast Cancer in the UK, 2013–2023	249
Table 96: Key Events Impacting Sales for HER2-Positive Breast Cancer in the UK, 2013–2023.....	251
Table 97: UK HER2-Positive Breast Cancer Market – Drivers and Barriers, 2013–2023	251
Table 98: Sales Forecast (\$m) for HER2-Positive Breast Cancer in Japan, 2013–2023	255
Table 99: Key Events Impacting Sales for HER2-Positive Breast Cancer in Japan, 2013–2023	257
Table 100: Japanese HER2-Positive Breast Cancer Market – Drivers and Barriers, 2013–2023	257
Table 101: Sales Forecast (\$m) for HER2-Positive Breast Cancer in China, 2013–2023	260
Table 102: Key Events Impacting Sales for HER2-Positive Breast Cancer in China, 2013–2023	262
Table 103: Chinese HER2-Positive Breast Cancer Market – Drivers and Barriers, 2013–2023	262
Table 104: HER2-Positive Breast Cancer Incidence, 2013–2023	304
Table 105: HER2-Positive Breast Cancer Drugs, Key Launch Dates	305
Table 106: HER2-Positive Breast Cancer Drugs, Key Patent Expiries	306
Table 107: Average Body Weight and Surface Area Across the 8MM.....	307
Table 108: Average Annual Cost of Therapy (\$) – Herceptin, Adjuvant.....	309
Table 109: Average Annual Cost of Therapy (\$) – Subcutaneous Herceptin, Adjuvant	310
Table 110: Average Annual Cost of Therapy (\$) – Perjeta, First Line.....	311
Table 111: Average Annual Cost of Therapy (\$) – Tykerb, First Line	312
Table 112: Average Annual Cost of Therapy (\$) – Kadcyla, Second Line	313
Table 113: Average Annual Cost of Therapy (\$)– Halaven, Fourth Line.....	313
Table 114: Average Annual Cost of Therapy (\$) – Abraxane, Fourth Line	314
Table 115: Average Annual Cost of therapy (\$) – Ixempra, Fourth Line	315
Table 116: Average Annual Cost of Therapy (\$) – Neratinib, Third Line.....	317

Table of Contents

Table 117: Physicians Surveyed by Country	320
---	-----

1.2 List of Figures

Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes	30
Figure 2: 8MM, Age-Standardized Incidence Rate of Breast Cancer, Ages ≥ 15 Years, Women, Cases per 100,000 Population, 2008.....	45
Figure 3: 8MM, Incidence Rate of Breast Cancer, Ages ≥ 15 Years, Women, Rate per 100,000 Population, 2008.....	46
Figure 4: US, Incidence Rate of Breast Cancer, All Ages, Women, Cases per 100,000 Population, 1975–2009.....	47
Figure 5: 5EU, Incidence Rate of Breast Cancer, Ages ≥ 15 Years, Women, Cases per 100,000 Population, 1975–2010	49
Figure 6: Japan, Incidence Rate of Breast Cancer, All Ages, Women, Cases per 100,000 Population, 2003–2008.....	50
Figure 7: 8MM, Relative Survival Rate for Breast Cancer, All Ages*, Women, %, 1991–2004**	52
Figure 8: 8MM, Diagnosed Incident Cases of Breast Cancer, Ages ≥ 20 Years, Women, N, 2013–2023	66
Figure 9: 8MM, Diagnosed Incident Cases of Breast Cancer, by Age, Women, N, 2013	69
Figure 10: 8MM, Diagnosed Incident Cases of Breast Cancer by Menopausal Status, Ages ≥ 20 Years, Women, N, 2013	70
Figure 11: 8MM, Diagnosed Incident Cases of Breast Cancer by Stage at Diagnosis, Ages ≥ 20 Years, Women, N, 2013	72
Figure 12: 8MM, Age-Standardized Diagnosed Incidence Rate of Breast Cancer, Ages ≥ 20 Years, Women, Cases per 100,000 Population, 2013.....	73
Figure 13: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer, Ages ≥ 20 Years, Women, N, 2013–2023	75
Figure 14: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Menopausal Status, Ages ≥ 20 Years, Women, N, 2013	76

Table of Contents

Figure 15: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Hormone Receptor Subtypes, Ages ≥20 Years, Women, N, 2013.....	78
Figure 16: Primary Completion Dates of Active Phase III Clinical Trials for Tykerb.....	121
Figure 17: Active Late-Stage Clinical Trials for Perjeta	126
Figure 18: Active Phase III Clinical Trials for Kadcyla	131
Figure 19: Active Phase III Clinical Trials for Afinitor.....	135
Figure 20: Clinical Trials for Halaven.....	145
Figure 21: HER2-Positive Breast Cancer – Phase II–III Pipeline, 2013	166
Figure 22: Gilotrif’s Clinical Development in Breast Cancer	167
Figure 23: Clinical and Commercial Positioning of Gilotrif	170
Figure 24: Neratinib’s Clinical Development	172
Figure 25: Clinical and Commercial Positioning of neratinib.....	174
Figure 26: Global Sales (\$m) of Branded Products for HER2-Positive Breast Cancer by Company, 2013–2023	200
Figure 27: Company Portfolio Gap Analysis in HER2-Positive Breast Cancer, 2013–2023.....	201
Figure 28: Global Sales for HER2-Positive Breast Cancer by Region, 2013–2023	217
Figure 29: Global Sales for HER2-Positive Breast Cancer by Drug Class, 2013–2023	218
Figure 30: Sales for HER2-Positive Breast Cancer in the US by Drug Class, 2013–2023.....	224
Figure 31: Sales for HER2-Positive Breast Cancer in France by Drug Class, 2013–2023	230
Figure 32: Sales for HER2-Positive Breast Cancer in Germany by Drug Class, 2013–2023	235
Figure 33: Sales for HER2-Positive Breast Cancer in Italy by Drug Class, 2013–2023	240
Figure 34: Sales for HER2-Positive Breast Cancer in Spain by Drug Class, 2013–2023	245

Table of Contents

Figure 35: Sales for HER2-Positive Breast Cancer in the UK by Drug Class, 2013–2023.....	250
Figure 36: Sales for HER2-Positive Breast Cancer in Japan by Drug Class, 2013–2023.....	256
Figure 37: Sales for HER2-Positive Breast Cancer in China by Drug Class, 2013–2023	261

Introduction

2 Introduction

2.1 Catalyst

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. When diagnosed at a very early stage, the prognosis is positive, with a five-year survival rate of nearly 100%. However, in the later stages of the disease, survival rapidly decreases. HER2-positive breast cancer is aggressive, and historically, has had a worse overall survival (OS) compared with HER2-negative disease, which is considered to be less aggressive. In 1998, the launch of the first HER2-targeted therapy, Herceptin (trastuzumab), revolutionized the treatment of the disease, bringing the OS close to that of HER2-negative breast cancer. The realization that introducing HER2-targeted therapies earlier into the disease management strategy could improve disease-free survival (DFS) has created a large market for HER2-directed therapies. Today, HER2-positive breast cancer patients are living longer with their disease, thanks to established disease management strategies using numerous combinations of chemotherapy with Herceptin and the tyrosine kinase inhibitor (TKI), Tykerb (lapatinib). During the forecast period from 2013–2023, GlobalData expects that the HER2-positive market will grow due to the aging populations in the US, 5EU, Japan, and China.

The realization that introducing HER2-targeted therapies earlier into the disease management strategy could improve disease-free survival (DFS) has created a large market for HER2-directed therapies.

Furthermore, with the new premium-priced agents, such as Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine) becoming established in the early lines of metastatic disease, physicians will have additional treatment options for patients. More therapies will be used in the neoadjuvant and adjuvant settings, and several pipeline agents are also being investigated in the non-metastatic market in this disease. A number of these agents are looking to address the greatest unmet need for HER2-positive breast cancer patients — brain metastases — which typically occur in the later lines of metastatic therapy and are caused by increasingly resistant disease.

2.2 Related Reports

- GlobalData (2014). Non-Small Cell Lung Cancer (NSCLC) – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update, April 2014, GDHC002EPIDR
- GlobalData (2014). Pancreatic Cancer – Opportunity Analysis and Forecasts to 2017, March 2014, GDHC016POA

Introduction

- GlobalData (2013). Bladder Cancer – Opportunity Analysis and Forecasts to 2017, December 2013, GDHC014POA

2.3 Upcoming Related Reports

- GlobalData (Q3 2014). HER2-Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2023
- GlobalData (Q3 2014). Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2023

Appendix

11.8 About GlobalData

GlobalData is a leading global provider of business intelligence in the healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports, and forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Japan, Singapore, and Australia.

11.9 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher, GlobalData.